Steffen Zeng
4Patents
3h-index
15Co-inventors
40Inventor score
Filing activity: Dec 23, 2008 → May 5, 2010
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US9011864B2 | Method of decreasing cytotoxic side-effects and improving efficacy of immunoconjugates | Chemistry; Metallurgy | 16 | Active |
| US9289509B2 | Uses of immunoconjugates targeting CD138 | Performing Operations; Transporting | 6 | Active |
| US9221914B2 | Agents targeting CD138 and uses thereof | Chemistry; Metallurgy | 5 | Active |
| US9387261B2 | Immunoconjugates targeting CD138 and uses thereof | Chemistry; Metallurgy | 3 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.